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The Kidney Disease: Improving Global Outcomes (KDIGO)
initiative organized a Controversies Conference on
glomerular diseases in November 2017. The conference
focused on the 2012 KDIGO guideline with the aim of
identifying new insights into nomenclature, pathogenesis,
diagnostic work-up, and, in particular, therapy of
glomerular diseases since the guideline’s publication. It was
the consensus of the group that most guideline
recommendations, in particular those dealing with therapy,
will need to be revisited by the guideline-updating Work
Group. This report covers general management of
glomerular disease, IgA nephropathy, and membranous
nephropathy.
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T he Kidney Disease: Improving Global Outcomes(KDIGO) initiative published its first guideline onglomerular diseases in 2012.1 Given the enormous
advances in understanding the pathogenesis of glomerular
diseases, identification of new diagnostic biomarkers, and
emerging therapies, about 100 experts from various disci-
plines (nephrology, pathology, rheumatology, pediatrics) and
organizations (academia, pharmaceutical industry) convened
on November 17–19, 2017. Through plenary and small group
discussions, the conference aimed to evaluate consensus and
controversies in nomenclature, general work-up and man-
agement of glomerular diseases, future needs in research, and,
in particular, the critical assessment of existing guideline
recommendations.
This first of 2 reports covers general management of
glomerular diseases. In addition, this report addresses 2
common forms of glomerulonephritis (GN), namely IgA
nephropathy (IgAN) and membranous nephropathy. Primary
podocytopathies, complement-mediated glomerular diseases,
lupus nephritis, antineutrophil cytoplasmic antibody–
associated nephritis, and monoclonal gammopathies of
renal significance will be covered in the second report. These
2 conference summaries will lay the basis for the guideline
updating process that began in August 2018.
GENERAL PRINCIPLES IN THE MANAGEMENT OF
GLOMERULAR DISEASE
This section will consider newer concepts and controversies in
the general management principles of glomerular disorders.
Disease-specific issues, applications, or exceptions to these
general statements will be discussed within each of the indi-
vidual glomerular disease sections. Additional broad-based
management principles for glomerular diseases may be
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found in chapter 2 of the 2012 KDIGO Clinical Practice
Guideline for Glomerulonephritis.1
Kidney Biopsy
The kidney biopsy remains the cornerstone for the evaluation
of glomerular disease.2,3 In very few and specific circum-
stances such as childhood steroid-sensitive nephrotic syn-
drome, diagnosis and treatment are often done without a
kidney biopsy. In adults this approach is uncommon but may
be considered in individual cases. For example, patients who
have normal kidney function, acute onset of nephrotic syn-
drome, and are positive for anti-phospholipase A2 receptor
(PLA2R) antibodies are likely to have membranous ne-
phropathy. Treatment could be initiated without biopsy if
such patients had a high risk of procedural complications, but
care must be taken as other diseases may emulate all of these
features.4,5
Kidney tissue is also critical for assessing the degree of
histologic activity and chronicity and to identify unexpected
features such as interstitial nephritis, acute kidney injury, and
crescents, all factors that might significantly impact disease
management.
The kidney biopsy should be interpreted in the context of
ethnicity, age, and hypertension, as these may modify the
background kidney histology. For instance, understanding the
“normal” range of age-related focal segmental glomerulo-
sclerosis in a population might allow a better estimate of the
extent of glomerular disease in an individual biopsy.6 Appli-
cation of other modifiers, such as ethnicity, needs to be
considered.
The value of kidney tissue is likely to expand significantly in
the near term. It is likely that taking a more system-related
approach to the biopsy will enhance its value by providing
more information important to diagnosis, prognosis, and
treatment. For example, all clinical trials have treatment fail-
ures suggesting variations between individuals in the molec-
ular pathways driving disease progression despite similar
histopathology. To develop targeted therapies, identification of
these pathways is necessary and will require a focus on
mechanisms operative at the tissue level rather than relying
solely on standard histologic findings. This also ties into the
new concept of immunologic versus clinical remission.5,7,8
The need for electron microscopy for every biopsy remains
controversial. It can be critical in some cases, for example, to
differentiate between immunologically mediated and adaptive
focal segmental glomerulosclerosis variants.9 Application at a
worldwide level may be difficult, but it could possibly be
leveraged by preservation of a small amount of tissue and, if
judged critical to management, sent to an electron micro-
scopy reference laboratory for evaluation.
Assessment of kidney function
Proteinuria. Most glomerular diseases are associated with
significant proteinuria. Although ratios of albumin-to-
creatinine or protein-to-creatinine (PCR) in random spot
urines are commonly used, recent data highlight the poor
agreement between these ratios and 24-hour urine protein
measurements.10 Although spot albumin-to-creatinine ratio
and PCR are helpful in general clinical management, they are
not sufficiently accurate when therapeutic decisions about
using high-risk medications are being made on small changes
in proteinuria.11,12 In such cases, a 24-hour urine protein
or PCR should be measured. Importantly, the PCR from an
intended 24-hour urine collection that is at least 50%
complete has been shown to accurately reflect 24-hour
proteinuria.13
In young children, obtaining a 24-hour urine collection is
usually not possible and PCR is the preferred means to assess
proteinuria. Monitoring serum albumin levels in nephrotic
patients also represents a valuable tool to indirectly assess the
extent of proteinuria.
GFR assessments. The gold standard for estimating renal
excretory function remains inulin or isotopic clearance
techniques, but these are expensive and require operator
expertise. Newer, accurate techniques to measure glomerular
filtration rate (GFR) are evolving.14 Presently, the Chronic
Kidney Disease Epidemiology Collaboration’s (CKD-EPI)
equation for estimating GFR is often used instead.15 Formulas
have also been developed for children.16,17 However, esti-
mated GFR (eGFR) equations have not been validated in
specific glomerular diseases and patient populations. In
addition, when estimating glomerular function in patients
with high-grade proteinuria, the majority of studies still use
24-hour urine collections for creatinine clearance. Errors
related to collection and laboratory measurements under
these conditions can induce up to 50% of errors in GFR
measurement.18–20 The accuracy of these methods may be
partially compensated by frequent longitudinal measurement
and use of data-smoothing techniques.21 A simple, reliable,
and inexpensive biomarker of kidney function is still wanting.
Hematuria. Macro- or microhematuria is associated with
almost all glomerular disorders and identification of red cell
casts may provide clues to nephritic diseases such as IgAN.
Qualitatively, the routine urine dipstick can distinguish the
presence or absence of microhematuria, but the capacity to
quantitate hematuria has pitfalls, including timing between
collection and examination, urine concentration, preparation
of the urine pellet, pH of the urine, and the expertise of the
examiner. The disappearance of hematuria, however, associ-
ated with complete clinical remission can be important in
assessing the activity of diseases such as IgAN and anti-
neutrophil cytoplasmic antibody vasculitis.22,23
Outcome measures. Regulatory agencies still grant
approval for drugs in GN based on the classic findings of
complete remission of proteinuria, as a positive outcome, and
end-stage kidney disease (ESKD) (or a 50% reduction in
eGFR), and/or mortality as negative outcomes. Recent col-
laborations among the US Food and Drug Administration,
the pharmaceutical industry, and members of nephrology
organizations, under the umbrella organization, the Kidney
Health Initiative, are developing alternative surrogate end-
points for drug approval. The first consensus meeting
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culminated in a decision to allow a 40% reduction in eGFR to
serve as an endpoint, but earlier endpoints are needed in these
rare diseases.24 In membranous nephropathy, recent data
suggest that complete remission could serve as a surrogate
endpoint and partial remission used as a basis for approval
under the accelerated approval program in the United
States.25 Both outcomes are supported by statistical tech-
niques that allow the prospective quantitation of the benefit
of a partial remission of proteinuria based on its duration in
an individual patient.26 The Kidney Health Initiative group is
currently evaluating surrogate endpoints in IgAN and lupus
nephritis.
Futility. The concept of futility can be critical to patient
management. This “point of no return” is usually defined by a
low eGFR, often < 30 ml/min per 1.73 m2 and/or kidney
biopsy that shows a high degree of irreversible chronic
changes.1 Noninvasive assessment of whole kidney chronicity/
fibrosis is not ready for clinical application.27 Currently, the
rate of change in kidney function is likely more important
than a single cross-sectional measurement of eGFR in
defining futility. Additionally, age and overall wellness should
be considered when determining futility.
The question of futility also extends to clinical trials. Fu-
tility criteria are often used to exclude patients from clinical
trials with the thought that risk will outweigh gain for such
patients. Therefore, many patients miss the opportunity to
participate in trials, complicating attainment of sample size
and generalizability of results. It may be helpful to have more
patient engagement in determining clinical trial eligibility. If
the treating physician thinks it is reasonable to consider a
clinical trial and their patient is fully informed, such patients
could be considered if futility criteria were less rigid. This
concept is commonly followed in clinical practice. Although
controversial, patient engagement may become more relevant
as low-risk treatments become available.
Quality of life and quality of health
Quality of life and health are important components of
determining treatment value and are increasingly used by
regulatory agencies to assess overall worth of a new treat-
ment.1 In glomerular diseases, patient-related outcomes and
patient-related outcome measurements are evolving, but
standards for clinical practice guidelines do not yet exist.
Other determinants of progression of kidney disease
In addition to well-established progression factors such as
persistent proteinuria, poorly controlled hypertension or
diabetes, smoking, or widespread cardiovascular disease,28
new evidence supports prematurity as having an impact on
nephron endowment and potentially limiting renal reserve
and increasing risk of progression in glomerular diseases
(Table 1).29 This can be approximated by birth weight, a
readily available, low-cost demographic. Its value within
specific diseases is still speculative, but it could be considered
as basic information that may affect treatment and outcomes
of glomerular diseases.
Another recently defined health risk factor is sleep hygiene.
From the National Health and Nutrition Examination Survey
in the CKD population, low-sleep duration and other related
disorders (e.g., restless legs syndrome, sleep apnea) were
associated with all-cause mortality and cardiovascular mor-
tality. Extrapolation into the glomerular disease population
seems relevant as this is a modifiable factor and can be
applied broadly to all patients.30
Weight reduction in obese patients may benefit glomerular
diseases.31–33 Small studies, focusing on diet and bypass sur-
gery, have shown at least short-term benefits. Weight reduc-
tion and sleep improvement are intriguing possible additions
to standard treatment approaches that are economical, widely
applicable, and that foster patient engagement.
Sex is another issue that is often considered to be an
important part of disease risk stratification in GN. Recent
data, however, suggest that different rates of progression are
more driven by the histologic category, blood pressure (BP),
and severity of proteinuria than by sex.34
Genetic testing in kidney disease
Genetic testing has rapidly evolved and its role has expanded
to include not only confirming clinical diagnoses, but also
establishing inheritance patterns, differentiating heteroge-
neous disorders, determining appropriate treatment, guiding
decisions about family planning, and determining the cause
of unexplained familial kidney disorders. It is also expected to
be used for identifying new risk factors for susceptibility and
progression. Currently cost and unclear clinical implications
limit the use of genetic testing.35,36
Management of complications of glomerular diseases
Hypertension. Hypertension control remains crucial to
the management of GN. Although some controversy remains,
data support a BP target of 125/75 mm Hg in the GN patient
with proteinuria >1 g/d. Critical to the management of
resistant hypertension is a careful review of the patient’s di-
etary sodium intake. Educating the patient on how to inter-
pret food labels and providing feedback by assessing sodium
intake with 24-hour urine sodium estimates are effective
strategies.37,38 Sodium restriction will not only lower BP, but
may enhance the antiproteinuric effects of renin–angiotensin
system (RAS) blockers. The Institute of Medicine currently
recommends limiting dietary sodium to <1500 mg/d (65
mmol/d), which is a 50% to 75% reduction from the average
North American intake. There are no clear data on optimal
sodium restriction in children.
Proteinuria reduction. Proteinuria reduction remains a
goal in virtually all glomerular diseases. The main approach is
through RAS blockade. An area of controversy is whether
angiotensin-converting enzyme inhibitors or angiotensin re-
ceptor blockers should be used alone, as dual therapy and/or
in combination with an aldosterone antagonist. Previously,
hyperkalemia and acute kidney injury outweighed benefits of
dual therapy, but recent studies indicate that with careful
monitoring, combination therapy can be safe.39 Nonetheless,
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the benefit for dual RAS blockade in GN with high-grade
proteinuria is not clear.39 A practical approach to amelio-
rating risks due to RAS blockers, particularly acute kidney
injury, is by providing “sick day instructions” to withhold or
decrease the dose of these medications during periods when
volume depletion may occur, as with vomiting or diarrhea.
Aldosterone blockade reduces cardiovascular mortality in
patients with heart failure and also reduces albuminuria.40–42
However, the absolute risk-benefit ratio for aldosterone
blockade in GN remains unclear.
The sodium-glucose transport proteins 2 (SGLT2) in-
hibitors may offer a new proteinuria reduction strategy.
However, in a recent study, short-term treatment with the
SGLT2 inhibitor dapagliflozin did not modify renal hemo-
dynamic function or attenuate proteinuria in nondiabetic
humans with focal segmental glomerulosclerosis, possibly
because of downregulation of renal SGLT2 expression in focal
segmental glomerulosclerosis.43 Several large studies are
currently investigating SGLT2 inhibitors in nondiabetic CKD
(e.g., The Study of Heart and Kidney Protection With
Empagliflozin [EMPA-KIDNEY], NCT03594110; Effects of
Dapagliflozin in Nondiabetic Patients With Proteinuria
[DIAMOND], NCT03190694; A Study to Evaluate the Effect
of Dapagliflozin on Renal Outcomes and Cardiovascular
Mortality in Patients With Chronic Kidney Disease [Dapa-
CKD], NCT03036150).
Hyperlipidemia. The accelerated vascular disease seen in
patients with CKD includes those with GN, and recent data
suggest this may be worse in some glomerular diseases than
others.44,45 Although traditionally statins have been used to
treat hyperlipidemia and are effective, target values may not
be achieved, especially in the new era of very low target low-
density lipoprotein levels. Novel powerful agents such as
proprotein convertase subtilisin/kexin type 9 inhibitors (e.g.,
evolocumab, alirocumab) need to be studied in the GN
population.46 Evidence that lipid-lowering therapy in children
is beneficial is of poor quality but needs to be explored given
their expected longevity.47 In contrast to cardiovascular
benefits of statins, renal benefits are not well established.48
Hypercoagulability. Concerning the risk-benefit ratio of
prophylactic anticoagulation in nephrotic patients, especially
in those with glomerular diseases associated with thrombotic
events, decision aids are available online particularly for pa-
tients with membranous nephropathy (www.med.unc.edu/
gntools).49,50 Whether non-vitamin-K antagonist oral anti-
coagulants can be safely used has only been demonstrated
above an eGFR of 30 ml/min per 1.73 m2. Effects of more
severe CKD and proteinuria on non-vitamin-K antagonist
oral anticoagulant metabolism and clearance require further
study.51
Risk of infection. There is a risk of infection with most of
the medications used to treat the glomerular diseases,
including common infections, in particular pneumonias, but
also more specific infectious complications such as hepatitis B
virus reactivation during immunosuppression52 or infections
that cluster in particular regions, such as pneumocystis in-
fections in Chinese patients.12 Thus, antimicrobial prophy-
laxis is needed as per regional practice. Specific infections are
also more common with certain drugs, such as infection with
encapsulated organisms during treatment with the comple-
ment inhibitor eculizumab. All patients who will be given this
therapy should receive meningococcal vaccination with the
multicomponent serogroup B vaccine,1,53 beginning at least 2
weeks before starting treatment. This is likely to become more
relevant in GN patients as specific complement inhibitors are
evaluated for C3 nephropathy and IgAN.
From a global perspective there is also the additional need
for careful evaluation of a patient’s potential for endemic
infections such as tuberculosis, hepatitis B, and parasites
based on geographic origins.
Future studies
Important areas of future research, aside from thosementioned
previously, include better and more rapid point-of-care
methods (e.g., for GFR, proteinuria, risk evaluations). In-
depth collaboration among pathologists, pharmacists, nurses,
and clinicians is essential.54 Accelerating new drug develop-
ment coupled with more sophisticated and efficient treatment
trials is critical to improving success. For example, cluster and
adaptive design methods can shorten trial time, reduce sample
size, and accelerate early development.54,55
Glomerular diseases are rare but represent a significant
percentage of the ESKD population and are one of the few
categories of kidney disease that are treatable. The majority
have slowly progressive courses, so to reach the outlined
goals, we need more specialized GN centers to acquire the
necessary sample size cohorts for clinical trials. A GN center
(hub) associated with several peripheral units (spokes) is one
useful design for connecting with patient advocacy groups
and sharing vital information across registries/biobanks.56,57
In addition, glomerular disease experts, advocacy groups,
and the pharmaceutical industry should be collaborating at all
Table 1 | Established and emerging risk factors for progression of kidney disease
Risk factors for progressive loss of GFR Emerging risk factors for progressive loss of GFR
 Persistent proteinuria
 Poorly controlled hypertension
 Poorly controlled diabetes mellitus
 Smoking
 Widespread cardiovascular disease
 Use of nephrotoxic drugs
 Prematurity (low birth weight) and other reasons for low nephron number29
 Low-sleep duration and other related disorders (e.g., restless legs syndrome, sleep apnea)30
 Obesity31–33
 Gender?34
GFR, glomerular filtration rate.
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phases of development to improve investigative strategies,
determine best trial designs, and assist in their execution.
IgA NEPHROPATHY
Pathogenesis
New information concerning the pathogenesis of IgAN has
become available (Figure 1)58:
 Poorly O-galactosylated IgA1 produced at mucosal surfaces
and its increased serum levels in IgAN likely reflect a defective
mucosal immune system.59 Poorly O-galactosylated IgA1
and circulating autoantibodies to galactose-deficient IgA1
have been reported to predict progression,60 but their value
in prognostication or disease monitoring has not been
properly tested when considered in addition to blood pres-
sure, eGFR, proteinuria, or the MEST-C score—mesangial
(M), endocapillary (E) hypercellularity, segmental sclerosis
(S), interstitial fibrosis/tubular atrophy (T), crescents (C)
(see Biomarkers and prediction of prognosis). Similarly, us-
ing a novel antibody-based assay, serum levels of poorly O-
galactosylated IgA1 were not sufficiently discriminatory to
warrant its use as a diagnostic or prognostic tool.61 A recent
genome-wide association study in IgAN identified suscepti-
bility gene loci involved in intestinal mucosal immunity.62 In
support, the Effect of Nefecon in Patients With Primary IgA
Nephropathy at Risk of Developing End-stage Renal Disease
(NEFIGAN) trial, which targeted budesonide to the distal
ileum, reduced proteinuria in patients with IgAN after 9
months of treatment.63 A confirmatory phase 3 trial is
currently underway.
 Mucosal activation of the innate immune response through
ligation of Toll-like receptors (TLR) engagement by mi-
crobes and other danger signals, and signaling through the
B-cell survival factors B-cell activating factor and a prolif-
eration inducing ligand are critical events regulating
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Figure 1 | Proposed pathogenesis of IgA nephropathy (IgAN) and potential therapeutic targets. (1) Mucosal infection primes naive B cells
to class switch to become IgA antibody-secreting cells (ASCs) through both T-cell–dependent (cytokine mediated) and T-cell–independent (Toll-
like receptor [TLR] ligation) pathways. (2) Some IgA ASCs mis-home to the systemic compartment during lymphocyte trafficking. (3) Displaced
IgAþ ASCs take up residence in systemic sites and secrete normal “mucosal-type” (poorly galactosylated and polymeric) IgA1 into the systemic
circulation. (4) IgA1 secretion by displaced mucosal ASC is augmented by TLR ligation from mucosal-derived pathogen-associated molecular
patterns, which have entered the systemic compartment. (5) IgA1 immune complexes form in the systemic circulation. Poorly galactosylated
polymeric IgA1 molecules are the substrate for immune complex formation and combine with IgG and IgA autoantibodies reactive to exposed
neoepitopes in the poorly galactosylated IgA1 hinge region. (6) IgA1 immune complexes deposit in the mesangium through a combination of
mesangial trapping and increased affinity of poorly galactosylated IgA1 for extracellular matrix components. Immune complex deposition
triggers a series of downstream pathways, including complement activation via the mannose-binding lectin and other pathways, leading to
glomerular injury and tubulointerstitial scarring. APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; MASP-2, mannan-binding
lectin-associated serine protease-2. Adapted from Boyd JK, Cheung CK, Molyneux K, et al. An update on the pathogenesis and treatment of IgA
nephropathy. Kidney Int. 2012;81:833–843,58 with permission. Copyright ª 2012 International Society of Nephrology.
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mucosal immunity, and are targets for therapeutic inter-
vention with hydroxychloroquine or B-cell activating fac-
tor/a proliferation inducing ligand inhibitors.64–66
 Glomerular injury in IgAN is associated with activation of
the complement system.67,68 This is supported by genetic
mapping and clinical reports of eculizumab rescuing cres-
centic IgAN.68–70 A monoclonal antibody targeting
mannan-binding lectin-associated serine protease 2, the
effector enzyme of the lectin pathway, has shown anti-
proteinuric effects in 4 IgAN patients, and a phase 3 trial is
now underway.71 Although these pathogenic mechanisms
have resulted in novel therapeutic possibilities, further ev-
idence from larger long-term trials is required before they
can be included in future guideline recommendations.
Biomarkers and prediction of prognosis
The MEST scoring system for IgAN offered the first opportu-
nity to use histology to predict renal outcome independent of
proteinuria, BP, and eGFR.72,73 The European Validation Study
of the Oxford Classification of IgAN (VALIGA) study
confirmed the association of M1, S1, and T1/2 with renal
outcomes, and the association of M1 and E1 with subsequent
increase in proteinuria.74 In children, MEST scoring yielded a
higher prevalence of proliferative lesions versus sclerotic le-
sions.74 When the MEST score in adults was combined with
eGFR, proteinuria, and BP at biopsy, it was possible to predict
renal outcome with the same accuracy as clinical data over 2
years of follow-up, and thereby the MEST score allowed risk
stratification at an earlier time point.75 A large analysis of IgAN
patients demonstrated that cellular or fibrocellular crescents
were independently associated with a higher risk of kidney
disease progression, especially in those not immunosup-
pressed.76 In addition, crescents in >25% of glomeruli were
associated with an increased risk of poor renal outcome even in
patients treated with immunosuppression, although this was
based on small subgroups and the results were not consistent
across all outcomes evaluated.76 Based on this study, MEST
now includes a C score of 1 or 2 (crescents <25% or >25%,
respectively). Importantly, MEST-C score was developed to
predict renal outcome and not to guide treatment or to predict
treatment response. Although observational data suggest that
E1 and crescents may predict outcomes differently in treated
versus untreated patients, and the benefits of steroidsmaydiffer
in patients with M1 or S1, there is currently insufficient evi-
dence to suggest that immunosuppression decisions should be
based on histology parameters.72,76–78 Amajor limitation is the
absence of a validated risk prediction model that allows inte-
gration of histology with clinical predictors to establish an ac-
curate individual prognosis.
New biomarkers are needed to further improve prediction
of renal prognosis in IgAN. Glomerular C4d deposition may
represent a marker of an adverse prognosis,79 but this finding
needs more external validation before it can be routinely
recommended. A small study demonstrated an association
between time-averaged microhematuria >5 red blood cells
per high-power field and the risk of ESKD especially when
combined with time-averaged proteinuria.23 However,
time-averaged values require the entire duration of follow-up,
which is not clinically relevant, and it is not clear whether the
association is independent of MEST-C and other established
clinical predictors.
There have been over 1000 derivation studies for biomarkers
in IgAN. To date, none have externally validated the assay
reproducibility and association with renal outcome using
commercially available platforms, and none have translated the
results into clinical practice by demonstrating that the
biomarker improves prediction beyond other readily available
risk factors.80 Currently, no biomarker is ready for clinical
application.
Treatment
Significant controversy surrounds the use of steroids in IgAN.
The Supportive Versus Immunosuppressive Therapy for the
Treatment of Progressive IgA Nephropathy (STOP-IgAN) trial
randomized patients to supportive treatment, or to steroids
alone, or steroids in conjunction with sequential cyclophos-
phamide and azathioprine based on eGFR. Immunosup-
pression transiently reduced proteinuria over 3 years but had
no impact on eGFR and only resulted in significant, partic-
ularly, infectious adverse events.81 Proteinuria reduction
occurred mostly in the steroid and not immunosuppressive
combination therapy group.82 Optimized supportive treat-
ment was associated with a very slow loss of kidney function
in the control group, so that the study was underpowered to
detect eGFR-based outcomes. The Therapeutic Evaluation of
Steroids in IgA Nephropathy Global Study (TESTING Low
Dose Study) (TESTING) trial randomized patients to 6
months of steroids or placebo and was terminated early after
an interim analysis revealed a high risk of infectious serious
adverse events including lethal Pneumocystis jirovecii pneu-
monia.12 There was a significant reduction in the risk of a
40% decline in eGFR or ESKD in the steroid group. The
kidney function loss in the control group was 4 times faster in
the TESTING trial than in the STOP-IgAN trial, suggesting a
higher-risk population and/or differences in supportive
therapy. In TESTING, the beneficial impact of steroids was
similar in patients with eGFR > or <50 ml/min per /1.73 m2.
This finding is consistent with analyses of other clinical trials
that also showed a benefit of immunosuppression at lower
eGFR but with an increased risk of adverse events.77,83 Future
guideline recommendations (Supplementary Table S1) will
need to include an assessment of the relative risks and benefits
of steroids in individual patients over a broader range of
eGFR, with careful consideration of infections and
prophylaxis.
Although previous studies suggested mycophenolate
mofetil (MMF) was not effective for treatment of IgAN,84,85 2
recent trials add conflicting information. A mostly Caucasian
trial was stopped early for futility because there was no MMF
effect on the proteinuria-based primary outcome.86 However,
a Chinese trial randomized patients to 6 months of full dose
steroids or lower dose steroids with MMF.87 After 1 year,
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complete proteinuria remission was similar between the 2
groups, but with fewer steroid-related adverse events in those
treated with MMF. This study reintroduces the possibility that
MMF may be effective for IgAN; however, there was very
infrequent use of RAS-blockade; it was not a multiethnic
study population and the follow-up duration was too short to
evaluate an effect on kidney function. Further studies will be
required before MMF can be considered for treatment in
IgAN. Both RAS-blockers and MMF may affect pregnancy
adversely and patients will need to understand this and ex-
ercise appropriate use of contraception when being treated.
Tonsillectomy remains a controversial therapy for IgAN. A
Japanese trial compared tonsillectomy with steroids versus
steroids alone and found marginally higher proteinuria
reduction in the tonsillectomy group but no impact on eGFR
over 12 months.88 Only one-half of the patients received RAS
blockade, and there was no long-term follow-up to evaluate
changes in eGFR. In a European cohort, tonsillectomy pa-
tients were propensity-score matched to control patients with
no benefit in change of GFR or proteinuria.89 Therefore,
tonsillectomy may only be considered in IgAN patients with
recurrent tonsillitis.
Although observational data suggest that IgAN incidence
and outcome may differ between Caucasians and Asians,90–92
there is currently insufficient evidence to suggest that treat-
ment approaches should differ by ethnicity. Possibly, sys-
tematic differences in study populations, other than ethnicity,
may explain different treatment responses.86, 93 Multiethnic
trials, such as the ongoing TESTING Low Dose trial
(ClinicalTrials.gov NCT01560052), are evaluating this issue
further.
Future studies
Trials of rituximab and tacrolimus have yielded negative re-
sults.94,95 Current trials address the spleen tyrosine kinase
inhibitor fostamatinib, and the B-cell activating factor and a
proliferation inducing ligand blocker atacicept (Figure 1). A
pilot study of the proteasome inhibitor bortezomib has just
been completed. Future multiethnic trials of other pharma-
cologic agents should incorporate therapeutic drug level
monitoring to help determine whether ethnic differences in
outcome may be related to pharmacokinetics versus differ-
ential disease response.
MEMBRANOUS NEPHROPATHY
Membranous nephropathy is characterized by subepithelial
glomerular immune complexes. The discovery of podocyte
antigens to which circulating antibodies are directed has been
a major breakthrough.96,97 This, and the reports of clinical
studies and trials mandate revisiting nearly all of 2012
KDIGO membranous nephropathy recommendations1
(Supplementary Table S2).
Terminology
The discovery of antibodies against intrinsic podocyte anti-
gens (PLA2R and thrombospondin-like domain 7A
[THSD7A]) established that membranous nephropathy is an
autoimmune disease. Emerging data point to the diagnostic,
prognostic, and disease-monitoring value of measuring anti-
PLA2R antibodies levels.8 This introduced a categorization
of membranous nephropathy based on the detectable auto-
antibodies versus nephropathy not associated with either
antibody. Membranous nephropathy associated with other
disease processes (infections, systemic lupus erythematosus,
sarcoidosis, malignancies) constitutes a separate category
(Figure 2).
Pathogenesis
Antibodies against PLA2R and THSD7A are present in 50%
to 80% and 2% to 4% of patients with membranous ne-
phropathy, respectively. The 2 serotypes coexist only occa-
sionally. PLA2R antibodies are uncommon in patients with
membranous nephropathy associated with malignancies.
Conversely, cancer may be more common among patients
with THSD7A antibodies, but the data are still insufficient to
direct malignancy screening approaches in membranous ne-
phropathy. PLA2R-associated membranous nephropathy is
linked to genetic polymorphisms in the PLA2R gene, which
seYoN
Other systemic diseases
(sarcoidosis, IgG4-related kidney
disease, Sjögren)
Cancer
PLA2R-
associated
(~70%)
Associated
with other
autoantibodies
(?%)
Infection
Systemic lupus
erythematosus
Drugs/
toxins
THSD7A–
associated
(~3%)
Pathogenically associated
with concurrent disease
Figure 2 | Proposed categorization of membranous nephropathy.
With the discovery of antibody target antigens in a majority of
patients with membranous nephropathy, a disease categorization is
emerging based on the detection and serotype of these antibodies.
This figure suggests a categorization based on the current knowledge
of such antibodies. The relative size of the disease categories and
their overlap is approximate (not to scale). Despite the specificity of
anti-M-type phospholipase A2 receptor (anti-PLA2R) antibodies for
primary membranous nephropathy, the presence of such antibodies
does not rule out the concurrence of infection, malignancy, or other
disease processes and does not obviate the need for an infectious
work-up and age-appropriate cancer screening. Analysis of the fre-
quency of detectable anti-PLA2R antibodies in patients with mem-
branous nephropathy and other diseases is low and is still evolving
with additional research. Recent studies have reported on the
detection of anti-PLA2R antibodies in a substantial minority of pa-
tients with hepatitis infection or with sarcoidosis. These findings do
not necessarily imply a pathogenic link between the concurrent
disease and membranous nephropathy. Emerging data suggest a
possible association between thrombospondin type 1 domain-
containing 7A (THSD7A) antibodies and cancer.
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provides additional evidence of the pathogenic role of this
autoantibody.98,99
Biomarkers: diagnosis and prediction of prognosis
Role of the kidney biopsy in diagnosis. Because PLA2R
antibodies predict membranous nephropathy with high
specificity, a kidney biopsy may not be needed in anti-
PLA2R–positive patients with a low risk of disease progres-
sion and/or a high risk of biopsy-related morbidity5,100
(Figure 3, Table 2). When immunosuppressive therapy is
contemplated, performing a kidney biopsy is still recom-
mended to exclude another concomitant process and to es-
timate the extent of chronic fibrosis. A kidney biopsy is
especially indicated in cases of nephrotic syndrome and acute
kidney injury because it may identify cases of membranous
nephropathy with crescentic GN (anti–glomerular basement
membrane or antineutrophil cytoplasmic antibody–associ-
ated) even in cases that are positive for anti-PLA2R. In anti-
PLA2R–negative patients, a kidney biopsy is needed to di-
agnose membranous nephropathy. In such patients, it is
important to look at whether PLA2R staining is present in the
glomeruli, because this will allow identification of patients
with PLA2R-associated membranous nephropathy. In selected
cases of membranous nephropathy, it may be important to
look at IgG subclasses in the kidney biopsy, with IgG1-
dominant staining being suggestive of secondary causes. The
specificity of THSD7A antibodies in diagnosing membranous
nephropathy is not well established.
The presence of PLA2R antibodies does not allow exclu-
sion of a concurrent infection or cancer.
Risk-stratification. Patients with membranous nephropa-
thy and subnephrotic proteinuria have excellent long-term
renal survival and do not need immunosuppression. Among
patients with nephrotic range proteinuria, disease severity
varies and prognosis ranges from spontaneous remission to
severe nephrotic syndrome and progression to ESKD. In such
patients, the risks of immunosuppression should not exceed
the short-term risks of nephrotic syndrome. The current risk
stratification of patients who need treatment (>6 months of
proteinuria >4 g/d) lacks specificity, as a substantial pro-
portion of such patients may still develop spontaneous
remission.101 Models that use other cutoff points or that
include the serial measurement of urinary low-molecular-
weight proteins, serum albumin, and eGFR may allow bet-
ter assessment of the risk of disease complications and/or
progression. Emerging data point to the prognostic value of
quantitatively measuring PLA2R antibody levels and possibly
PLA2R antibody evitageNevitisoP
High risk*
High risk* *ksir woL*ksir woL Kidney biopsy
Risk assessment Risk assessment
Nephrotic syndrome
No kidney biopsy
Supportive therapy
Supportive
therapy
Supportive therapy and consider
immunosuppressive therapy
Kidney biopsy
Figure 3 | Proposed algorithm for the diagnosis of membranous nephropathy. *See Table 2 for definitions of low and high risk. PLA2R, M-
type phospholipase A2 receptor.
Table 2 | Factors associated with the risk of progressive loss
of kidney function in patients with membranous
nephropathy
Low risk High risk
Proteinuria
<3.5 g/d
 Serum creatinine >1.5 mg/dl (133 mmol/l)
 Decrease in eGFR by $ 20% over any time period
during the preceding 12 months not explained
otherwisea
 Proteinuria >8 g/d for > 6 mo
 Presence of low-molecular-weight proteinuria
 Urine IgG > 250 mg/24 h
 PLA2R antibody levels and evolutionb
eGFR, estimated glomerular filtration rate; PLA2R, M-type phospholipase A2
receptor.
The table lists factors that have been associated with increased risk of disease
progression. The presence of any of these risk factors may suffice to consider
immunosuppressive therapy but risk increases if several factors are present. Treating
physicians should take these factors and the patient’s symptoms, comorbidities, and
risks of complications into consideration when determining the timing and choice of
therapy.
aeGFR decline not attributable to causes other than membranous nephropathy such
as initiation of renin–angiotensin system blockers or intravascular volume depletion.
bInsufficient data are currently available to determine the cutoff level of PLA2R
antibody associated with increased risk of progression.
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qualitatively defining the spread of their target epitopes.102,103
In PLA2R-positive patients, low antibody levels appear to
predict a greater likelihood of spontaneous remission than
high levels. Conversely, patients with antibodies targeting 2 or
3 target epitope domains may be less likely to develop a
spontaneous remission.
A recent study showed that changes in PLA2R antibody
levels during follow-up were correlated with changes in
proteinuria.104 Because this study included treated patients,
data are lacking on the value of monitoring the trend of
PLA2R antibody levels prior to immunosuppressive therapy
to guide the decision to initiate such treatment or the choice
of therapeutic agents.
Treatment
Besides preservation of kidney function and proteinuria
remission, future goals of treatment should include
improvement of patient-related outcomes and quality-of-life
measures (for which validated instruments should be devel-
oped) and prevention of cardiovascular and thromboembolic
events,45 infections, and patient mortality.
There is consensus that immunosuppression should be
started in the presence of decreasing GFR or, in partic-
ular, severe life-threatening nephrotic syndrome. In pa-
tients with minimal symptoms and preserved kidney
function, delaying immunotherapy while maximizing
treatment of proteinuria, hypertension, and hyperlipid-
emia for up to 3 years may be acceptable.105 The avail-
ability of less toxic treatments may lead to earlier
initiation of immunotherapy to allow more rapid disap-
pearance of symptoms of nephrotic syndrome. Apart
from small kidney size there is no other threshold for
which treatment is deemed futile. Therapy can stabilize
even patients with eGFR <30 ml/min per 1.73 m2. A
kidney biopsy is valuable in identifying acute kidney
injury or assessing the severity of fibrosis.
Treatment with immunosuppressive agents
All patients should undergo screening for infections and an
age-appropriate screening for malignancies prior to
commencing immunosuppressive therapy.
Alkylating agents remain the only agents proven effective
in preventing ESKD or death.106 Given their toxicity, they
should only be prescribed by experienced physicians and
restricted to patients at high risk of progression. Current and
previous smokers may be at particularly increased risk for
subsequent bladder or lung cancer associated with exposure
to cytotoxic agents. Special consideration should likewise be
given to patients of childbearing age because of the risk of
infertility associated with these agents. Historically, treatment
with an alkylating agent had been cyclical and accompanied
by pulses of i.v. methylprednisolone. Other regimens are used
in clinical practice, including daily cyclophosphamide and
omission of pulses of methylprednisolone.
Other immunosuppressive agents only used proteinuria
reduction as the endpoint. Therapy with calcineurin in-
hibitors induced remissions with similar frequency as cyclo-
phosphamide but was associated with a higher relapse
rate.107,108 Continued daily use of a calcineurin inhibitors
may maintain remission; however, the consequences of long-
term therapy are unknown. In 1 controlled trial, chlor-
ambucil, but not cyclosporine, reduced eGFR loss in mem-
branous nephropathy with renal insufficiency.109
In the Evaluate Rituximab Treatment for Idiopathic
Membranous Nephropathy (GEMRITUX) study, rituximab
was more effective than placebo in inducing remissions after
17 months.101 The nonresponse rate to rituximab was
approximately 35%. A recent retrospective propensity-
Table 3 | PLA2R antibodies: predictor of disease course and treatment response
Author and study description PLA2R Ab level
Patients with
complete or partial
remission (%) P value or HRs
PLA2R assay
method
Hofstra 2012112 41–175 U/ml 38%
Analysis of spontaneous remissions 176–610 U/ml 31% P < 0.01 ELISA: in house
>610 U/ml 4%
Ruggenenti 2015111 14–86 RU/ml 82% HR: 4.2 (95% CI: 1.9–9.2; P < 0.0001)a
All patients treated with rituximab 87–204 RU/ml 59% HR: 2.3 (95% CI: 1.0–5.2;
P ¼ 0.048)a
ELISA: EuroImmune
>204 RU/ml 37% 1
Dahan 2017101 <275 RU/ml 43%b OR: 3.5 (95% CI: 1.1–10.7; P ¼ 0.03)c ELISA: EuroImmune
Randomized controlled trial of rituximab >275 RU/ml 20%b 1
Ab, antibody; CI, confidence interval; ELISA, enzyme linked immunosorbent assay; HR, hazard ratio(s); OR, odds ratio; PLA2R, M-type phospholipase A2 receptor; RU, relative
unit(s).
Complete remission was defined as proteinuria <0.2, <0.3, or <0.5 g/d; partial remission as <3.0 g/d with$ 50% reduction from baseline. Spontaneous remission was defined
as complete or partial remission without any immunosuppressive therapy.
aCompared with highest tertile of baseline anti-PLA2R level (>204 RU/ml).
bPersonal communication.
cBy multivariate analysis, odds ratio of complete or partial remission at last follow-up (median: 17.0 [interquartile range: 12.5–24.0] months) compared with group with
baseline anti-PLA2R >275 RU/ml, independent from treatment group (nonimmunosuppressive antiproteinuric therapy with or without rituximab), age, sex, baseline pro-
teinuria, serum albumin, and creatinine.
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matched cohort study suggested lower partial remission rates
with rituximab versus cyclophosphamide.110 Measurement of
PLA2R antibodies might aid in predicting treatment response
(Table 3).111 The choice of first-line therapy therefore still
awaits direct head-to-head trials. It is likely that the choice of
therapy may be determined by improved risk-stratification
models.
Disease monitoring. PLA2R antibody levels may be valu-
able for monitoring treatment and follow-up. Complete re-
missions are almost always associated with the disappearance
of PLA2R antibodies. Although declining antibody levels may
precede clinical remission, it is currently unclear to what
extent a decrease predicts a subsequent remission. Therefore,
serial monitoring of PLA2R antibodies during treatment re-
quires further study. During remission of proteinuria, there is
no evidence to support preemptive therapy based on rising
antibody levels alone. Still, measuring PLA2R antibodies in
patients with a recurrence or worsening of proteinuria should
help distinguish between relapse and other causes of pro-
teinuria. Persistent anti-PLA2R antibodies prior to kidney
transplantation are associated with an increased risk of
recurrence of membranous nephropathy in the allograft.
There are insufficient data to assess whether a kidney trans-
plant should be delayed until the antibodies become negative
and for how long. Conditions under which a repeat biopsy or
screening workup for infections, malignancy, or other causes
of nephrotic syndrome should be done are not well defined.
Future studies
While anti-PLA2R antibody assays are reasonably comparable
for diagnostic purposes, they quantitatively differ. Any risk-
stratification or disease-monitoring model based on anti-
body levels will require harmonization and calibration of
tests. To what extent and in what capacity antibody levels may
be used in defining surrogate endpoints in clinical trials re-
quires formal evaluation.
Additional research is needed to develop more accurate
risk-stratification models that incorporate other biomarkers
of disease in addition to proteinuria—including qualitative
and quantitative measures of autoantibodies.
We expect data from theMembranous Nephropathy Trial of
Rituximab (MENTOR) study (which compared rituximab vs.
cyclosporine) in the short term. The report of the Sequential
Therapy With Tacrolimus and Rituximab in Primary Mem-
branous Nephropathy (STARMEN) study (which compares
tacrolimus and rituximab vs. the cyclical cyclophosphamide
and corticosteroids “Ponticelli” regimen) is expected in 2019.
Studies using combinations of existing drugs and the evalu-
ation of novel agents directed at different immunological
targets may improve the frequency and/or duration of
complete remissions.
With respect to trial design, complete remission
(proteinuria <0.3 g/d combined with stable GFR) may be
used as a surrogate endpoint. Partial remission (50% reduc-
tion of proteinuria to a level <3.5 g/d) should be evaluated as
a surrogate endpoint. The role of serum albumin in defining
partial remission needs further formal evaluation, as well as
harmonization of the serum albumin assays.
CONCLUSIONS
While old problems such as the best way of assessing kidney
function, kidney disease activity, and proteinuria still linger in
nephrology, major progress has been made in our under-
standing of disease pathogenesis in IgAN and membranous
nephropathy. The number of randomized trials in these dis-
eases has grown steadily and several phase 3 trials are
currently underway. Recent attempts to define surrogate
outcomes, such as full remission in membranous nephropa-
thy, will certainly further bolster this field.
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